These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
738 related articles for article (PubMed ID: 17684491)
1. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491 [TBL] [Abstract][Full Text] [Related]
2. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202 [TBL] [Abstract][Full Text] [Related]
3. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181 [TBL] [Abstract][Full Text] [Related]
4. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287 [TBL] [Abstract][Full Text] [Related]
6. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. Naumann U; Maass P; Gleske AK; Aulwurm S; Weller M; Eisele G Int J Oncol; 2008 Oct; 33(4):759-65. PubMed ID: 18813789 [TBL] [Abstract][Full Text] [Related]
7. The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. Sliwa M; Markovic D; Gabrusiewicz K; Synowitz M; Glass R; Zawadzka M; Wesolowska A; Kettenmann H; Kaminska B Brain; 2007 Feb; 130(Pt 2):476-89. PubMed ID: 17107968 [TBL] [Abstract][Full Text] [Related]
8. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Zhang F; Lee J; Lu S; Pettaway CA; Dong Z Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637 [TBL] [Abstract][Full Text] [Related]
9. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Nakamura H; Siddiqui SS; Shen X; Malik AB; Pulido JS; Kumar NM; Yue BY Mol Vis; 2004 Oct; 10():703-11. PubMed ID: 15475878 [TBL] [Abstract][Full Text] [Related]
10. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Lakka SS; Gondi CS; Yanamandra N; Olivero WC; Dinh DH; Gujrati M; Rao JS Oncogene; 2004 Jun; 23(27):4681-9. PubMed ID: 15122332 [TBL] [Abstract][Full Text] [Related]
12. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612 [TBL] [Abstract][Full Text] [Related]
13. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. Kominsky SL; Doucet M; Brady K; Weber KL J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147 [TBL] [Abstract][Full Text] [Related]
14. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Ashley DM; Kong FM; Bigner DD; Hale LP Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409 [TBL] [Abstract][Full Text] [Related]
15. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Gramatzki D; Pantazis G; Schittenhelm J; Tabatabai G; Köhle C; Wick W; Schwarz M; Weller M; Tritschler I Oncogene; 2009 Jul; 28(28):2593-605. PubMed ID: 19465936 [TBL] [Abstract][Full Text] [Related]
16. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Yoo YA; Kang MH; Kim JS; Oh SC Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246 [TBL] [Abstract][Full Text] [Related]
17. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line. Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206 [TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas. Tysnes BB; Haugland HK; Bjerkvig R Invasion Metastasis; 1997; 17(5):270-80. PubMed ID: 9876221 [TBL] [Abstract][Full Text] [Related]
19. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells. Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532 [TBL] [Abstract][Full Text] [Related]